Showing results 1 to 1 of 1
Issue Date | Title | Journal Title |
---|---|---|
2022 | Response Rate and Safety of a Neoadjuvant Pertuzumab, Atezolizumab, Docetaxel, and Trastuzumab Regimen for Patients With ERBB2-Positive Stage II/III Breast Cancer: The Neo-PATH Phase 2 Nonrandomized Clinical Trial | JAMA ONCOLOGY |